Prion Protein (PrP)

Prion Protein (PrP)

<div class="infobox infobox-protein">

| Property | Value |
|----------|-------|
| Protein Name | Cellular Prion Protein |
| Gene | PRNP |
| UniProt ID | P04156 |
| PDB ID | 1QLX, 1QM0, 2W9D, 4DGI |
| Molecular Weight | ~33-35 kDa (membrane-bound form) |
| Subcellular Localization | Cell membrane (GPI-anchored), cytoplasm |
| Protein Family | Prion protein family |

</div>

Overview

The cellular prion protein (PrP^C) is a GPI-anchored glycoprotein expressed predominantly in the central nervous system[@riek1996]. While its physiological function remains incompletely understood, PrP^C is best known for its central role in prion diseases—fatal neurodegenerative disorders caused by conformational conversion to the disease-associated isoform PrP^Sc (scrapie prion protein)[@prusiner2013]. This page covers PrP structure, normal neurological functions, disease mechanisms, and therapeutic approaches.

Structure

The prion protein is a 253-amino acid GPI-anchored protein with a distinctive domain organization[@riek1996]:

Domain Organization

• Signal peptide (residues 1-23): N-terminal signal sequence for ER targeting
• Flexible N-terminal domain (residues 23-120): Unstructured, copper-binding region
• C-terminal globular domain (residues 121-231): Ordered, globular, contains three alpha-helices and two beta-strands
• GPI anchor signal (residues 232-253): Glycosylphosphatidylinositol anchor for membrane attachment

Structural Features

...

Prion Protein (PrP)

<div class="infobox infobox-protein">

| Property | Value |
|----------|-------|
| Protein Name | Cellular Prion Protein |
| Gene | PRNP |
| UniProt ID | P04156 |
| PDB ID | 1QLX, 1QM0, 2W9D, 4DGI |
| Molecular Weight | ~33-35 kDa (membrane-bound form) |
| Subcellular Localization | Cell membrane (GPI-anchored), cytoplasm |
| Protein Family | Prion protein family |

</div>

Overview

The cellular prion protein (PrP^C) is a GPI-anchored glycoprotein expressed predominantly in the central nervous system[@riek1996]. While its physiological function remains incompletely understood, PrP^C is best known for its central role in prion diseases—fatal neurodegenerative disorders caused by conformational conversion to the disease-associated isoform PrP^Sc (scrapie prion protein)[@prusiner2013]. This page covers PrP structure, normal neurological functions, disease mechanisms, and therapeutic approaches.

Structure

The prion protein is a 253-amino acid GPI-anchored protein with a distinctive domain organization[@riek1996]:

Domain Organization

• Signal peptide (residues 1-23): N-terminal signal sequence for ER targeting
• Flexible N-terminal domain (residues 23-120): Unstructured, copper-binding region
• C-terminal globular domain (residues 121-231): Ordered, globular, contains three alpha-helices and two beta-strands
• GPI anchor signal (residues 232-253): Glycosylphosphatidylinositol anchor for membrane attachment

Structural Features

• Alpha-helices: Three alpha-helices (A: 144-154, B: 173-194, C: 200-228)
• Beta-strands: Two beta-strands (B1: 128-131, B2: 161-164) form a small beta-sheet
• Disulfide bond (Cys179-Cys214): Stabilizes the C-terminal domain
• Glycosylation sites: Two N-linked glycosylation sites (Asn181, Asn197)
• Copper binding: Octarepeat region (residues 51-91) binds Cu²⁺ ions

PrP^Sc Conformation

The disease-associated PrP^Sc isoform differs dramatically in[@prusiner2013]:

• Beta-sheet content: Increased from ~10% to ~40-50%
• Protease resistance: C-terminal fragment (residues ~81-231) becomes proteinase K-resistant
• Aggregation propensity: Forms amyloid fibrils and plaques
• Glycosylation pattern: Distinct glycoform ratios compared to PrP^C

Normal Function in the Nervous System

Neuroprotection

• Antioxidant activity: Copper-bound PrP^C exhibits SOD-like activity[@brown1997]
• Cellular stress response: Upregulated under oxidative stress conditions
• Anti-apoptotic signaling: Activates PI3K/Akt and MAPK pathways

Synaptic Function

• Synaptic maintenance: Essential for synaptic structure and function[@colby2011]
• Neurotransmission: Modulates GABAergic and glutamatergic signaling
• Synaptic plasticity: Involved in [long-term potentiation](/mechanisms/long-term-potentiation) (LTP)

Copper Homeostasis

• Copper binding: The octarepeat region binds up to 4 Cu²⁺ ions[@brown1997]
• Copper uptake: May function as a copper influx transporter
• Copper metabolism: Regulates neuronal copper balance

Cell Signaling

• Membrane microdomains: Enriched in lipid rafts for signaling
• Protein interactions: Binds to various ligands including Cu²⁺, A-beta, and laminin
• Neuroprotective complexes: Forms complexes with A-beta to potentially neutralize its toxicity

Neurodevelopment

• Neuronal differentiation: Involved in neural progenitor cell function
• Myelin maintenance: Important for oligodendrocyte survival
• Axonal guidance: May participate in axonal pathfinding

Role in Neurodegenerative Diseases

Prion Diseases

Prion diseases, also called transmissible spongiform encephalopathies (TSEs), are caused by conversion of PrP^C to PrP^Sc[@prusiner2013]:

Human Prion Diseases

Creutzfeldt-Jakob Disease (CJD)

• Most common human prion disease
• Sporadic (sCJD), genetic (gCJD), and iatrogenic (iCJD) forms
• Rapidly progressive dementia, ataxia, myoclonus
• Typical survival: months to 2 years

Fatal Familial Insomnia (FFI)

• Caused by D178N mutation with methionine at codon 129
• Progressive insomnia, autonomic dysfunction, cognitive decline
• Selective thalamic degeneration

Gerstmann-Sträussler-Scheinker Syndrome (GSS)

• Autosomal dominant prion disease
• Cerebellar ataxia, slowly progressive dementia
• Younger onset than CJD (40-60 years)

Kuru

• Historical prion disease in Papua New Guinea
• Transmitted through ritualistic cannibalism
• Cerebellar ataxia, tremors

Animal Prion Diseases

• Scrapie: Sheep and goat prion disease
• Bovine Spongiform Encephalopathy (BSE): "Mad cow disease"
• Chronic Wasting Disease (CWD): Deer, elk, and moose

Pathogenic Mechanisms

Conformational Conversion

Nucleation-dependent polymerization

• PrP^Sc seeds template-driven conversion of PrP^C
• Exponential amplification of PrP^Sc aggregates
• Seeding threshold determines disease incubation period

Strain diversity

• Different PrP^Sc conformations encode strain properties
• Strains differ in incubation periods, neuropathology, and species barrier
• Glycoform ratios (PrP^Sc di-, mono-, non-glycosylated) characterize strains

Neurotoxicity Mechanisms

Loss of function

• Conversion depletes functional PrP^C
• Loss of neuroprotective signaling
• Synaptic dysfunction

Gain of toxic function

• PrP^Sc aggregates are directly neurotoxic
• Membrane disruption by oligomeric species
• Activation of apoptotic pathways

Cellular dysfunction

• Endoplasmic reticulum stress: [UPR](/entities/unfolded-protein-response) activation
• Mitochondrial dysfunction: Complex I inhibition, [ROS](/entities/reactive-oxygen-species) production
• Calcium dysregulation: Impaired calcium homeostasis
• [Autophagy](/entities/autophagy) impairment: Accumulation of autophagic vacuoles
• Synaptic failure: Loss of synaptic proteins and function

Neuroinflammation

• Microglial activation
• Cytokine release (IL-1β, IL-6, TNF-α)
• [Complement system](/entities/complement-system) activation

Alzheimer's Disease Connection

PrP^C interacts with [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptide[@lauren2009]:

• Aβ binding: PrP^C binds to Aβ oligomers with high affinity
• Toxicity mediation: PrP^C may mediate Aβ-induced synaptic dysfunction
• Memory deficits: Aβ-PrP^C interaction contributes to memory impairment in AD models

Genetic Factors

The PRNP gene (chromosome 20p13) shows polymorphism at codon 129[@prusiner2013]:

• Methionine (M) or Valine (V): Homozygosity (M/M or V/V) increases sporadic CJD risk
• D178N mutation: Causes FFI when coupled with M129
• P102L mutation: Most common GSS mutation
• E200K mutation: Most common genetic CJD mutation (worldwide)

Therapeutic Targeting

Current Challenges

• [Blood-brain barrier](/entities/blood-brain-barrier): Limits drug delivery to CNS
• Conformational conversion: Difficult to target with traditional inhibitors
• Strain diversity: Different PrP^Sc conformations require broad-spectrum approaches

Therapeutic Strategies

1. Anti-PrP Antibodies

• Monoclonal antibodies: Target PrP^C or PrP^Sc epitopes[@white2003]
• Intrabodies: Intracellular antibodies to neutralize intracellular PrP
• Passive immunization: Antibody delivery to clear PrP^Sc

2. Small Molecule Inhibitors

• Copper chelators: Disrupt metal-mediated aggregation
• Polyphenol derivatives: (e.g., epigallocatechin gallate) inhibit conversion
• Phenylbenzamides: Bind to PrP and prevent aggregation
• Aniline derivatives: PrP^Sc formation inhibitors

3. Gene Therapy

• RNAi: Knockdown of PRNP expression
• Antisense oligonucleotides (ASOs): Reduce PrP^C levels
• CRISPR/Cas9: Gene editing approaches (preclinical)

4. Immunomodulation

• Microglial modulation: Reduce neuroinflammation
• Complement inhibition: Block complement-mediated damage

5. Protein-Based Approaches

• Dominant-negative PrP: Mutant PrP that prevents conversion
• Decoy peptides: Compete with endogenous PrP for conversion

Clinical Trials

• Antisense oligonucleotides: Trials ongoing for genetic prion disease
• Antibody therapies: Several in preclinical development
• Copper-based therapies: Limited clinical benefit observed

Key Publications

[Prusiner, S.B. et al. (1993) Molecular structure of the prion protein (Cold Spring Harbor Laboratory Press)](https://doi.org/10.1101/SQB.1993.58.01.006)

[Prusiner, S.B. (1997) Prion diseases and the BSE crisis (Science)](https://doi.org/10.1126/science.278.5336.245)

[Brown, D.R. et al. (1997) The cellular prion protein binds copper in vivo (Nature)](https://doi.org/10.1038/37054)

[Colby, D.W. & Prusiner, S.B. (2011) Prions (Cold Spring Harbor Perspectives in Biology)](https://doi.org/10.1101/cshperspect.a006833)

[Lauren, J. et al. (2009) Cellular prion protein as a receptor for amyloid-beta (Nature)](https://doi.org/10.1038/nature08516)

[White, A.R. et al. (2003) Monoclonal antibodies against prion protein (Journal of Neurochemistry)](https://doi.org/10.1046/j.1471-4159.2003.02152.x)

Cross-References

• [PRNP Gene](/genes/prnp) — Gene encoding prion protein
• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD connection to PrP
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) — Related amyloid mechanisms
• [Creutzfeldt-Jakob Disease](/diseases/creutzfeldt-jakob) — Primary prion disease
• [Protein Aggregation](/mechanisms/protein-aggregation) — Aggregation mechanisms

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Creutzfeldt-Jakob Disease](/diseases/creutzfeldt-jakob)
• [Protein Aggregation](/mechanisms/protein-aggregation)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Riek, R. et al., (1996) NMR structure of the mouse prion protein domain PrP(121-231) (1996)](https://doi.org/10.1038/381571a0)

[Unknown, Prusiner, S.B. (2013) Biology and genetics of prions causing neurodegeneration (Nature Reviews Neuroscience) (2013)](https://doi.org/10.1038/nrn3733)

[Brown, D.R. et al., (1997) The cellular prion protein binds copper in vivo (Nature) (1997)](https://doi.org/10.1038/37054)

[Unknown, Colby, D.W. & Prusiner, S.B. (2011) Prions (Cold Spring Harbor Perspectives in Biology) (2011)](https://doi.org/10.1101/cshperspect.a006833)

[Lauren, J. et al., (2009) Cellular prion protein as a receptor for amyloid-beta (Nature) (2009)](https://doi.org/10.1038/nature08516)

[White, A.R. et al., (2003) Monoclonal antibodies against prion protein (Journal of Neurochemistry) (2003)](https://doi.org/10.1046/j.1471-4159.2003.02152.x)